36 results about "Clinical reaction" patented technology

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.

It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding.

The present invention provides a method to quantitatively measure the response of a patient to an immune-modulator drug that will aid clinicians in the determination of the optimal combination / posology of immunosuppressant / immune-modulator drugs. In addition, this method will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place. Furthermore, this method will significantly reduce side effects of immunosuppressant drugs, optimizing therapeutic scheme and dosages, enabling the determination of the most effective immunosuppression regimen at the lower dosages for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization.

The invention relates to methods for determining the likelihood of the formation of a clinical response in an individual to therapy with an immunomodulatory agent for treatment of a disease or condition of the individual.

The invention relates to methods for predicting a clinical response to B-lymphocyte inhibiting or depleting therapies (BCIDT) using expression levels of genes of the Type I INF pathway. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with B-lymphocyte inhibiting or depleting therapy. More in particular, the invention relates to a method for prognosticating the clinical response of a patient to treatment with a soluble BCID or TCID agent, said method comprising the steps of obtaining at least two samples from said patient wherein a first sample has not been exposed to a soluble BCID or TCID agent and wherein at least a second sample has been exposed to a soluble BCID or TCID agent, determining the level of an IFN-I type response in said at least two samples, comparing the level of the IFN-I type response in said first sample with the level of the IFN-I type response in said at least second sample and prognosticating said clinical response from said comparison.

The invention discloses a pill for treating chronic lymphocytic thyroiditis and a preparation method, belonging to the field of traditional Chinese medicines. The effective components of the pill disclosed by the invention are composed of the following raw materials: 65-80 g of Chinese yam, 63-76 g of radix pseudostellariae, 60-73 g of immature bitter orange, 57-70 g of wolfberry, 55-67 g of semen litchi, 53-65 g of radix bupleuri, 50-62 g of white atractylodes rhizome, 43-55 g of the root of three-nerved spicebush, 40-52 g of glossy privet fruit, 38-50 g of stellaria aquatica, 35-47 g of tendril-leaved fritillary bulb, 32-45 g of pericarpium citri reticulatae viride, 30-42 g of fructus forsythiae, 28-40 g of rhizoma atractylodis, 25-37 g of liquorice, 23-35 g of allium macrostemon, 20-33 g of rose, 18-30 g of fingered citron, 15-28 g of selfheal, 12-25 g of sea horse, 9-22 g of oyster, 6-15 g of turtle shell, 4-10 g of pumex, and 2-7 g of air potato. The selected medicinal materials in the invention accord with monarch, ministerial and adjuvant principles; aiming at pathogenesis, treatment is carried out according to different symptoms; both symptoms and root causes are treated; the pill disclosed by the invention has the effects of tonifying the spleen and kidney, promoting blood circulation to remove blood stasis and resolving hard lump, and has the advantages of being good in absorption effect, obvious in curative effect and free from toxic and side effects and poor in clinical reaction; and in addition, found from clinical verifications, the pill disclosed by the invention has higher curative rate to chronic lymphocytic thyroiditis.